{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:06:39Z","timestamp":1794708399541,"version":"4.9.1"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This international study aimed to assess the effect of imatinib discontinuation in paediatric patients with chronic myeloid leukaemia (<jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>) after deep molecular remission (<jats:styled-content style=\"fixed-case\">DMR<\/jats:styled-content>) had been achieved and maintained for at least 2\u00a0years. The primary endpoint of this analysis was the molecular relapse\u2010free survival, estimated by the non\u2010parametric Kaplan\u2010Meier method. Major endpoint was the estimated rate of patients without molecular relapse at 6\u00a0months. Fourteen patients were enrolled; 4 patients maintained <jats:styled-content style=\"fixed-case\">DMR<\/jats:styled-content> with a follow\u2010up of 24 (two patients), 34 and 66\u00a0months, respectively, whereas 10 patients relapsed. All molecular relapses occurred within 6\u00a0months (median 3\u00a0months, range 1\u20136) after imatinib discontinuation. The overall probability of maintaining <jats:styled-content style=\"fixed-case\">DMR<\/jats:styled-content> at 6\u00a0months was 28\u00b76%. No parameters associated with molecular relapse could be identified. Keeping in mind the rarity of paediatric <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>, which contributed to the small size of the cohort, our findings illustrate that imatinib cessation after sustained <jats:styled-content style=\"fixed-case\">DMR<\/jats:styled-content> is successful in only limited numbers of patients, whereas much higher rates are reported in adult patients. Further research is needed to extend the cohort of paediatric <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content> patients who might achieve treatment\u2010free remission with an ideal prerequisite of predicting the occurrence of molecular relapse l after imatinib cessation.<\/jats:p>","DOI":"10.1111\/bjh.15826","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T02:21:39Z","timestamp":1551925299000},"page":"718-724","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the <scp>STOP IMAPED<\/scp> study"],"prefix":"10.1111","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6259-9918","authenticated-orcid":false,"given":"Clara M. A.","family":"de Bruijn","sequence":"first","affiliation":[{"name":"Departments of Paediatric Oncology\/Haematology Beatrix Children's Hospital University Medical Centre Groningen University of Groningen Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Millot","sequence":"additional","affiliation":[{"name":"Departments of Paediatric Oncology\/Haematology Poitiers University Hospital Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[{"name":"Paediatric Haemato\u2010Oncology Medical Faculty Technical University Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Borisevich","sequence":"additional","affiliation":[{"name":"Belarusian Research Centre for Paediatric Oncology, Haematology and Immunology Minsk Belarus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brons","sequence":"additional","affiliation":[{"name":"Departments of Paediatric Oncology Radboud University Nijmegen Medical Centre Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Lausen","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, Rigshospitalet University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline S. J. M.","family":"de Bont","sequence":"additional","affiliation":[{"name":"Departments of Paediatric Oncology\/Haematology Beatrix Children's Hospital University Medical Centre Groningen University of Groningen Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30087-X"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.10.001"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu490"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0707841"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30066-2"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24495"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490003"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194522"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12977"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.9597"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70201-7"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1446"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.21989"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2010.08.060"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200201000-00006"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7114"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.007"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24521"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25090"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.03.020"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2604-x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.115"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30192-X"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.104"},{"key":"e_1_2_9_29_1","first-page":"76","article-title":"Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem\u2010cell transplantation","volume":"368","author":"Suttorp M.","year":"2010","journal-title":"Hematology American Society of Hematology Education Program"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0179-9"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0137"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15826","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15826","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15826","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T12:39:01Z","timestamp":1694349541000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,6]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1111\/bjh.15826"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15826","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,6]]},"assertion":[{"value":"2018-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}